Saeed Nemati - Cancer Research Center, Cancer Institute, Tehran University Medical of Sciences, Tehran, Iran
Maryam Hadji - Faculty of Social Sciences, Tampere University, Tampere, Finland
Parissa Seifi - Cancer Research Center, Cancer Institute, Tehran University Medical of Sciences, Tehran, Iran
Mohammad Shirkhoda - Department of Surgery, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
Mojtaba Vand Rajabpour - Cancer Research Center, Cancer Institute, Tehran University Medical of Sciences, Tehran, Iran
Nazanin Rajaei - Cancer Research Center, Cancer Institute, Tehran University Medical of Sciences, Tehran, Iran
Mahdi Aghili - Radiation Oncology Department, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
Mohammad Ali Mohagheghi - Cancer Research Center, Cancer Institute, Tehran University Medical of Sciences, Tehran, Iran
Kazem Zendehdel - Cancer Biology Research Center, Cancer Institute, Tehran University Medical of Sciences, Tehran, Iran

Background: Iran is a high-risk area with a poor prognosis for esophageal cancer. We conducted the present study to evaluate the survival rate of esophageal cancer after the introduction of neo-adjuvant chemo-radiation at the Cancer Institute of Iran. Method: We performed a retrospective cohort study and abstracted the data of ۴۲۱ patients who referred to the Cancer Institute of Iran between ۲۰۰۷ and ۲۰۱۱. Life table and Kaplan-Meier approaches were applied to estimate ۱-, ۳-, and ۵-year survival rates and corresponding ۹۵% confidence intervals (CI). Multiple Cox regression model was recruited for investigating the association between ۵-year survival rate and prognostic factors. Results: We found that ۱-, ۳-, and ۵-year survival rates were ۶۶.۷%, ۲۸.۲, and ۲۰.۹%, respectively. The hazard ratio (HR) was significantly higher among the patients who has received definitive chemo-radiation therapy (Hazard ratio (HR) = ۲.۲, ۹۵% confidence interval (CI): ۱.۱, ۴.۲), surgery (HR= ۲.۰ ۹۵% CI: ۱.۰, ۳.۷), and palliative care (HR= ۴.۲, ۹۵% CI: ۲.۱, ۱.۸) compared with those who received neo-adjuvant chemo-radiation and surgery. We also found that the ۵-year survival rate was doubled in the current study conducted between ۲۰۰۷ and ۲۰۱۱ (۲۰.۹%) compared with the previous one conducted between ۱۹۹۷ and ۲۰۰۶ (۱۰.۰%). Additionally, a considerable improvement was observed in ۱- and ۳-year survival rate of esophageal cancer at the Cancer Institute of Iran. Conclusion: Following the administration of neo-adjuvant chemo-radiation therapy, the prognosis of esophageal cancer has improved significantly at the Cancer Institute of Iran during the last decade. More data from other cancer centers and provinces of Iran are required.

Esophagus, Neoplasms, staging, Chemoradiation, Survival